Ra Capital Management, L.p. sold $391k of HOWL
owner at Werewolf Therapeutics, Inc.. 565,167 shares at an average of $0.69, traded May 8, 2026, filed May 12, 2026.
Score components
- +12Role10% owner
- +16Trade size$391k at market
- 0Share of holdings soldSold 9.1% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-000485, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 8, 2026 | SOpen-market sale Common Stockindirect: See footnotes | -351,514 | $0.71 | $250k | 5,885,968 | May 12, 2026 |
| May 8, 2026 | SOpen-market sale Common Stockindirect: See footnotes | -25,012 | $0.71 | $18k | 418,813 | May 12, 2026 |
| May 11, 2026 | SOpen-market sale Common Stockindirect: See footnotes | -81,678 | $0.67 | $55k | 5,804,290 | May 12, 2026 |
| May 11, 2026 | SOpen-market sale Common Stockindirect: See footnotes | -5,812 | $0.67 | $3,894 | 413,001 | May 12, 2026 |
| May 12, 2026 | SOpen-market sale Common Stockindirect: See footnotes | -94,432 | $0.64 | $60k | 5,709,858 | May 12, 2026 |
| May 12, 2026 | SOpen-market sale Common Stockindirect: See footnotes | -6,719 | $0.64 | $4,300 | 406,282 | May 12, 2026 |
Related signals
Other insiders at Werewolf Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $45k 143,199 shares | -100% | |
| 29Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $47k 157,084 shares | -52% | |
| 31Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $146k 416,911 shares | -9% | |
| 31Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $174k 448,836 shares | -9% | |
| 38Weak | Werewolf Therapeutics, Inc. | Ra Capital Management, L.p. owner | $254k 678,226 shares | -12% | |
| 13Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $28k 76,928 shares | -20% | |
| 14Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $43k 105,565 shares | -22% | |
| 16Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $64k 139,803 shares | -22% | |
| 16Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $66k 141,106 shares | -18% | |
| 17Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $87k 191,762 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.